Introduction: Transobturator tape (TOT) surgery has been associated with increased overactive bladder (OAB) although much controversy exists. Methods: In a cross-sectional study, women who underwent TOT surgery for pure stress incontinence (MonarcTM) answered the 6 questions of the symptom bother (SB) subscale of the OAB questionnaire – short form (OABq-SF) and an additional question regarding whether symptoms began after surgery. Women with SB score over the 4th quartile (≥30/100) were reassessed after a longer follow-up. Patients from primary care were recruited as controls. Results: We recruited 213 patients (135 in the TOT group and 78 age-adjusted controls). The mean age of operated patients was 58.7 ± 10.1 years with a mean follow-up of 25.9 ± 13.2 months. OABq-SF SB scores did not differ between the TOT group and controls (respectively, 18.5 ± 30 and 15.5 ± 6.7, p = 0.202). A total of 48% patients reported no relationship between symptoms and surgery. Highly symptomatic operated patients were reassessed after a longer follow-up (46.3 ± 10.6 months). The mean score in the second follow-up (n = 25) was not statistically different from the first assessment (46.4 ± 22.7 and 58.1 ± 19.8, p = 0.059). Conclusions: Women who underwent TOT surgery did not show increased OAB SB scores when compared to controls. Our study suggests that OAB symptoms may thus be present but overlooked during initial clinical assessment.

1.
Botros SM, Miller JJ, Goldberg RP, Gandhi S, Akl M, Beaumont JL, et al: Detrusor overactivity and urge urinary incontinence following trans obturator versus midurethral slings. Neurourol Urodyn 2007; 26: 42–45.
2.
Serati M, Braga A, Athanasiou S, Tommaselli GA, Caccia G, Torella M, et al: Tension-free vaginal tape-obturator for treatment of pure urodynamic stress urinary incontinence: efficacy and adverse effects at 10-year follow-up. Eur Urol 2017; 71: 674–679.
3.
Abraham N, Vasavada S: Urgency after a sling: review of the management. Curr Urol Rep 2014; 15: 400.
4.
Liang CC, Hsieh WC, Huang L: Outcome of coexistent overactive bladder symptoms in women with urodynamic urinary incontinence following anti-incontinence surgery. Int Urogynecol J 2017; 28: 605–611.
5.
Lee SK, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, et al: Impact of transobturator tape treatment on overactive bladder symptoms, particularly nocturia, in patients with mixed urinary incontinence. Korean J Urol 2014; 55: 520.
6.
Palva K, Nilsson CG: Prevalence of urinary urgency symptoms decreases by mid-urethral sling procedures for treatment of stress incontinence. Int Urogynecol J 2011; 22: 1241–1247.
7.
Gamble TL, Botros SM, Beaumont JL, Goldberg RP, Miller JJ, Adeyanju O, et al: Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol 2008; 199: 696.e1–e7.
8.
Acquadro C, Kopp Z, Coyne KS, Corcos J, Tubaro A, Choo MS, et al: Translating overactive bladder questionnaires in 14 languages. Urology 2006; 67: 536–540.
9.
Biardeau X, Zanaty M, Aoun F, Benbouzid S, Peyronnet B: Approach and complications associated with suburethral synthetic slings in women: systematic review and meta-analysis. Prog Urol 2016; 26: 254–269.
10.
Antunes-Lopes T, Coelho A, Pinto R, Barros SC, Cruz CD, Cruz F, et al: Urinary neurotrophin levels increase in women with stress urinary incontinence after a midurethral sling procedure. Urology 2017; 99: 49–56.
11.
Viereck V, Rautenberg O, Kociszewski J, Grothey S, Welter J, Eberhard J: Midurethral sling incision: indications and outcomes. Int Urogynecol J 2013; 24: 645–653.
12.
Mouracade P, El Abiad S, Roy C, Lang H, Jacqmin D, Saussine C: Correlation of -introital ultrasound with LUTS after sling surgery. Int Urogynecol J 2010; 21: 1261–1264.
13.
Serati M, Braga A, Sorice P, Siesto G, Salvatore S, Ghezzi F: Solifenacin in women with de novo overactive bladder after tension-free obturator vaginal tape – is it effective? J Urol 2014; 191: 1322–1326.
14.
Donovan RJ, Holman CD, Corti B, Jalleh G: Face-to-face household interviews versus telephone interviews for health surveys. Aust N Z J Public Health 1997; 21: 134–140.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.